We describe a 53-year-old man with HIV-1 who received allogeneic CCR5Δ32/Δ32 hematopoietic stem cell transplantation (HSCT) in 2013 to treat acute myeloid leukemia. Four years after analytic treatment interruption (ATI), the absence of viral rebound and the lack of immunological correlates of HIV-1 antigen persistence provide convincing evidence for HIV-1 cure.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohn, L. B. et al. The biology of the HIV-1 latent reservoir and implications for cure Strategies. Cell Host Microbe 27, 519–530 (2020). A review article on the mechanisms contributing to HIV-1 persistence during antiretroviral therapy.
Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation report of 2 cases. Ann. Intern. Med. 161, 319–327 (2014). This paper describes two patients in whom allogeneic stem cell transplantation with CCR5 wild-type donor cells resulted in 12 and 32 weeks of antiretroviral-free HIV-1 remission followed by a subsequent viral rebound.
Hütter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009). This article reports on the ‘Berlin patient’ — the first patient cured of HIV-1 by using a CCR5Δ32/Δ32 stem cell donor to treat his acute myeloid leukemia.
Eberhard, J. M. et al. Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Sci. Transl. Med. 12, eaay9355 (2020). This study provides an in-depth longitudinal characterization of the T cell compartment in a cohort of 16 HIV-1 patients after allogeneic HSCT.
Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 27, 2085–2098 (2021). A review article that provides an overview of the recent progress made related to HIV-1 cure, highlighting remaining knowledge gaps, and identifying priority research areas.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Jensen, B-E. O. et al. In-depth virological and immunological characterization of HIV-1 cure after 13 CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation. Nat. Med. https://doi.org/10.1038/s41591-023-02213-x (2023).
Rights and permissions
About this article
Cite this article
HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation. Nat Med 29, 547–548 (2023). https://doi.org/10.1038/s41591-023-02215-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02215-9
